Engineered Platelet for In Situ Natural Killer Cell Activation to Inhibit Tumor Recurrence
Source abstract
Abstract
Natural killer (NK) cells offer profound advantages against tumor recurrence due to their unique immunological behavior. NK cell therapies associated with the antibody-dependent cell-mediated cytotoxicity (ADCC) effect have made remarkable progress while being limited by insufficient antibody binding and the exhausted state of NK cells in the postsurgical immunosuppressive microenvironment. Leveraging the adherence of PLT to tumor cells, we developed an exogenously implanted platelet (PLT)-based NK cell-driven system (PLT-IgG-IL15) to improve the identifiability of residual tumors with IgG antibody labeling for NK cells catching and engaging, which consequently restored the ADCC effect and promoted the recovery of their killing function. Furthermore, interleukin-15 (IL-15) participated in the augmentation of NK cell function. Collectively, PLT-IgG-IL15 served as an NK cell tumor cell engager as well as an NK cell charger, achieving a <40% recurrence rate in mouse tumor models.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune Cell Function and Interaction · CAR-T cell therapy research · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
Funding
Jiangsu Provincial Key Research and Development Program · Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China
References (43)
Show source-provided references
1. 10.6004/jnccn.2020.001610.6004/jnccn.2020.0016 ↗
2. 10.1002/ctm2.2410.1002/ctm2.24 ↗
3. Bald T. · 2020 · 147 · 61
4. 10.1038/s41573-019-0052-110.1038/s41573-019-0052-1 ↗
5. 10.1038/nri304410.1038/nri3044 ↗
6. 10.1186/s12943-020-01238-x10.1186/s12943-020-01238-x ↗
7. 10.1007/s12026-011-8231-010.1007/s12026-011-8231-0 ↗
8. 10.1016/j.ccell.2017.06.00910.1016/j.ccell.2017.06.009 ↗
9. 10.1182/blood-2009-01-20046910.1182/blood-2009-01-200469 ↗
10. 10.1186/1479-5876-6-2510.1186/1479-5876-6-25 ↗
11. 10.1007/s40263-021-00875-010.1007/s40263-021-00875-0 ↗
12. 10.3389/fimmu.2020.0177110.3389/fimmu.2020.01771 ↗
13. 10.3390/cancers1302031210.3390/cancers13020312 ↗
14. 10.3389/fimmu.2015.0036810.3389/fimmu.2015.00368 ↗
15. 10.1002/adma.20180439510.1002/adma.201804395 ↗
16. 10.1016/j.canlet.2016.02.02410.1016/j.canlet.2016.02.024 ↗
17. 10.1007/BF0272534110.1007/BF02725341 ↗
18. 10.1016/j.semcancer.2022.01.00610.1016/j.semcancer.2022.01.006 ↗
19. 10.1080/08923973.2020.174273310.1080/08923973.2020.1742733 ↗
20. 10.3390/ijms22211137810.3390/ijms222111378 ↗
21. 10.3389/fimmu.2019.0303810.3389/fimmu.2019.03038 ↗
22. 10.1097/SLA.0b013e31826fcbdb10.1097/SLA.0b013e31826fcbdb ↗
23. 10.1182/blood-2014-08-53158210.1182/blood-2014-08-531582 ↗
24. 10.1038/s41551-016-001110.1038/s41551-016-0011 ↗
25. 10.1186/s13045-018-0669-210.1186/s13045-018-0669-2 ↗
26. 10.1038/s41467-022-29388-010.1038/s41467-022-29388-0 ↗
27. 10.1182/blood.202101153210.1182/blood.2021011532 ↗
28. 10.1158/1078-0432.CCR-20-457510.1158/1078-0432.CCR-20-4575 ↗
29. 10.1038/s41591-021-01651-910.1038/s41591-021-01651-9 ↗
30. 10.1038/s41590-019-0511-110.1038/s41590-019-0511-1 ↗
31. 10.1126/scitranslmed.aaf234110.1126/scitranslmed.aaf2341 ↗
32. 10.1038/s41571-020-0426-710.1038/s41571-020-0426-7 ↗
33. 10.3389/fimmu.2020.61466710.3389/fimmu.2020.614667 ↗
34. 10.1016/j.stem.2020.05.00810.1016/j.stem.2020.05.008 ↗
35. 10.1002/ijc.2899710.1002/ijc.28997 ↗
36. 10.1002/JLB.MR0718-269R10.1002/JLB.MR0718-269R ↗
37. 10.1182/blood.V122.21.2283.228310.1182/blood.V122.21.2283.2283 ↗
38. 10.1126/sciadv.aba856410.1126/sciadv.aba8564 ↗
39. 10.1021/accountsmr.2c0004210.1021/accountsmr.2c00042 ↗
40. 10.1016/j.apsb.2021.09.02110.1016/j.apsb.2021.09.021 ↗
41. 10.1146/annurev.immunol.22.012703.10470210.1146/annurev.immunol.22.012703.104702 ↗
42. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
43. 10.1038/s41590-020-0728-z10.1038/s41590-020-0728-z ↗